Latest News

Announcing our new headquarters in Cambridge, UK

One Vision Park

Nuclera is proud to announce that it has found a new home for its global headquarters working in partnership with Lateral, a UK-based real estate investment firm.  The new office will consolidate three existing Nuclera facilities on the Cambridge Science Park into a single 30,000 sq ft location on the Vision Park. The consolidation and expansion allows the company to gain operational efficiencies, increase collaboration, and bolster recruitment efforts by providing a modern space for employees to work. The move further accelerates the company’s path towards the commercialization of the eProtein™ desktop bioprinter and enables its mission to make proteins accessible


The new headquarters, due to open in late 2022, is a short distance from Cambridge city center. Located next to the guided busway, the site provides both convenient amenities and flexible commuting options for employees and visitors.  The company sought the new space less than a year after a successful Series B raise of $58m enabled them to expand personnel across key functions and ramp operations.


Nuclera’s eProtein™ bioprinter will allow researchers to accelerate discoveries and treatments by delivering on-demand, benchtop access to proteins. Researchers will soon be able to seamlessly move from protein screening to scaled-up expression on an accelerated time frame in all market segments.  

Nuclera co-founder and CEO Michael Chen said, “The scale of our work and team is expanding at a rapid pace. Following our recent series B raise we have secured top talent across key positions and are rapidly progressing in our mission to make proteins accessible via game-changing technology. We believe Lateral’s unique lab space focus mirrors our own ambition for better service and innovation in this sector.”

JLL and SMB advised Lateral and Taylor Wessing acted for Nuclera.

Want to know more about our mission to change synthetic biology?

Our mission is simple: provide high-quality genes and proteins at your benchtop.

Get in touch